‘High hopes for treatment’: Australian stakeholder perspectives of the clinical translation of advanced neurotherapeutics for rare neurological diseases
Health Expectations · 2024
DOI: 10.1111/hex.14063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Expectations, 2024. Verfasst von Christina Q Nguyen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Paediatrics and Child Health, University of New South Wales Medicine and Health, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Rare Diseases, Nervous System Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Cerebral Palsy Alliance Research Foundation, Medical Research Council.
Abstract (Originalsprache)
Introduction
Advanced therapies offer unprecedented opportunities for treating rare neurological disorders (RNDs) in children. However, health literacy, perceptions and understanding of novel therapies need elucidation across the RND community. This study explored healthcare professionals' and carers' perspectives of advanced therapies in childhood‐onset RNDs.
Methods
In this mixed‐methodology cross‐sectional study, 20 healthcare professionals (clinicians, genetic counsellors and scientists) and 20 carers completed qualitative semistructured interviews and custom‐designed surveys. Carers undertook validated psychosocial questionnaires. Thematic and quantitative data analysis followed.
Results
Participants described high positive interest in advanced therapies, but low knowledge of, and access to, reliable information. The substantial ‘therapeutic gap’ and ‘therapeutic odyssey’ common to RNDs were recognised in five key themes: (i) unmet need and urgency for access; (ii) seeking information; (iii) access, equity and sustainability; (iv) a multidisciplinary and integrated approach to care and support and (v) difficult decision‐making. Participants were motivated to intensify RND clinical trial activity and access to advanced therapies; however, concerns around informed consent, first‐in‐human trials and clinical trial procedures were evident. There was high‐risk tolerance despite substantial uncertainties and knowledge gaps. RNDs with high mortality, increased functional burdens and no alternative therapies were consistently prioritised for the development of advanced therapies. However, little consensus existed on prioritisation to treatment access.
Conclusions
This study highlights the need to increase clinician and health system readiness for the clinical translation of advanced therapeutics for RNDs. Co‐development and use of educational and psychosocial resources to support clinical decision‐making, set therapeutic expectations and promotion of equitable, effective and safe delivery of advanced therapies are essential. Patient or Public Contribution Participant insights into the psychosocial burden and information need to enhance the delivery of care in this formative study are informing ongoing partnerships with families, including co‐production and dissemination of psychoeducational resources featuring their voices hosted on the Sydney Children's Hospitals Network website SCHN Brain-Aid Resources .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Discipline of Paediatrics and Child Health, University of New South Wales Medicine and Health, Sydney, New South Wales, Australia.
- Department of Neurology, Sydney Children's Hospital Network, Sydney, New South Wales, Australia.
- Centre for Clinical Genetics, Sydney Children's Hospital Network, Sydney, New South Wales, Australia.
- Behavioural Science Unit, Kids Cancer Centre, Sydney Children's Hospital, Sydney, New South Wales, Australia.
- Children's Hospital Westmead Clinical School, Faculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, Australia.
- Population Child Health Research Group, University of New South Wales, Sydney, New South Wales, Australia.
ORCID-Profile: Christina Q Nguyen, Didu S T Kariyawasam, Kristine Alba-Concepcion, Sarah E Grattan, Elizabeth E Palmer, Kate Hetherington, Claire E Wakefield, Russell C Dale, Sue Woolfenden, Shekeeb Mohammad, Michelle A Farrar
Förderung
- National Health and Medical Research Council
- Cerebral Palsy Alliance Research Foundation
- Medical Research Council
Zitieren
APA
Nguyen, C. Q., Kariyawasam, D. S. T., Ngai, T. S. J., Nguyen, J., Alba-Concepcion, K., Grattan, S. E., Palmer, E. E., Hetherington, K., Wakefield, C. E., Dale, R. C., Woolfenden, S., Mohammad, S., & Farrar, M. A. (2024). ‘High hopes for treatment’: Australian stakeholder perspectives of the clinical translation of advanced neurotherapeutics for rare neurological diseases. Health Expectations. https://doi.org/10.1111/hex.14063
Vancouver
Nguyen CQ, Kariyawasam DST, Ngai TSJ, Nguyen J, Alba-Concepcion K, Grattan SE, et al. ‘High hopes for treatment’: Australian stakeholder perspectives of the clinical translation of advanced neurotherapeutics for rare neurological diseases. Health Expectations. 2024. doi:10.1111/hex.14063
BibTeX
@article{Nguyen2024,
author = {Nguyen, Christina Q and Kariyawasam, Didu S T and Ngai, Tsz Shun Jason and Nguyen, James and Alba-Concepcion, Kristine and Grattan, Sarah E and Palmer, Elizabeth E and Hetherington, Kate and Wakefield, Claire E and Dale, Russell C and Woolfenden, Sue and Mohammad, Shekeeb and Farrar, Michelle A},
title = {‘High hopes for treatment’: Australian stakeholder perspectives of the clinical translation of advanced neurotherapeutics for rare neurological diseases},
journal = {Health Expectations},
year = {2024},
doi = {10.1111/hex.14063}
}
EUVIMED